|
|
Volumn 33 Suppl 3, Issue , 2009, Pages
|
|
Anti-TNF-alpha treatment strategies: results and clinical perspectives.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTIINFLAMMATORY AGENT;
CERTOLIZUMAB PEGOL;
IMMUNOGLOBULIN F(AB) FRAGMENT;
INFLIXIMAB;
MACROGOL DERIVATIVE;
MONOCLONAL ANTIBODY;
TUMOR NECROSIS FACTOR ALPHA;
ARTICLE;
CROHN DISEASE;
DRUG ANTAGONISM;
ENTERITIS;
HUMAN;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REMISSION;
TREATMENT OUTCOME;
ULCERATIVE COLITIS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
COLITIS, ULCERATIVE;
CROHN DISEASE;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
INFLAMMATORY BOWEL DISEASES;
POLYETHYLENE GLYCOLS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REMISSION INDUCTION;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
MLCS;
MLOWN;
|
|
EID: 78650190825
PISSN: None
EISSN: 22107401
Source Type: Journal
DOI: 10.1016/s0399-8320(09)73156-2 Document Type: Article |
|
Times cited : (14)
|
|
References (0)
|
